HBM Holdings Ltd’s (HKG: 2142) wholly-owned subsidiary, Nona Biosciences, has announced a significant licensing agreement with the UK pharmaceutical giant AstraZeneca. The deal revolves around a pre-clinical monoclonal antibody (mAb) program, marking a substantial step forward in the development of innovative therapies.
Under the terms of the agreement, AstraZeneca will make an upfront payment of USD 19 million to Nona Biosciences. Additionally, the company is on track to receive USD 10 million in expected near-term milestone payments. The total potential value of the deal could reach up to USD 575 million, contingent upon the achievement of development, regulatory, and commercial milestones, plus tiered royalties based on net sales. The agreement also contains provisions for further payments should AstraZeneca decide to exercise its option.- Flcube.com
